Although the system of activity of botulinum poison (BTX) is deeply examined, numerous unanswered inquiries remain in regard to the creation and clinical properties of the two BTX definitions right now supported for corrective use. In this brief review, we have explained the main portion of this audit. These inquiries are investigated in detail: Neuromodulators past, present, future BTX type A, newer Type E, and innovations on the horizon with an accentuation on the most significant and uncovering research in the writing.